Literature DB >> 16030277

Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women.

Paul M Ridker1, Nader Rifai, Nancy R Cook, Gary Bradwin, Julie E Buring.   

Abstract

CONTEXT: Current guidelines for cardiovascular risk detection are controversial with regard to the clinical utility of different lipid measures, non-high-density lipoprotein cholesterol (non-HDL-C), lipid ratios, apolipoproteins, and C-reactive protein (CRP).
OBJECTIVE: To directly compare the clinical utility of total cholesterol, low-density lipoprotein cholesterol (LDL-C), HDL-C, non-HDL-C, apolipoproteins A-I and B(100), high-sensitivity CRP, and the ratios of total cholesterol to HDL-C, LDL-C to HDL-C, apolipoprotein B(100) to apolipoprotein A-I, and apolipoprotein B(100) to HDL-C as predictors of future cardiovascular events in women. DESIGN, SETTING, AND PARTICIPANTS: Prospective cohort study of 15,632 initially healthy US women aged 45 years or older (interquartile range, 48-59 years) who were enrolled between November 1992 and July 1995. All participants were followed up over a 10-year period for the occurrence of future cardiovascular events. MAIN OUTCOME MEASURE: Hazard ratios (HRs) and 95% confidence intervals (CIs) for first-ever major cardiovascular events (N = 464) according to baseline levels of each biomarker.
RESULTS: After adjustment for age, smoking status, blood pressure, diabetes, and body mass index, the HRs for future cardiovascular events for those in the extreme quintiles were 1.62 (95% CI, 1.17-2.25) for LDL-C, 1.75 (95% CI, 1.30-2.38) for apolipoprotein A-I, 2.08 (95% CI, 1.45-2.97) for total cholesterol, 2.32 (95% CI, 1.64-3.33) for HDL-C, 2.50 (95% CI, 1.68-3.72) for apolipoprotein B(100), 2.51 (95% CI, 1.69-3.72) for non-HDL-C, and 2.98 (95% CI, 1.90-4.67) for high-sensitivity CRP (P<.001 for trend across all quintiles). The HRs for the lipid ratios were 3.01 (95% CI, 2.01-4.50) for apolipoprotein B(100) to apolipoprotein A-I, 3.18 (95% CI, 2.12-4.75) for LDL-C to HDL-C, 3.56 (95% CI, 2.31-5.47) for apolipoprotein B(100) to HDL-C, and 3.81 (95% CI, 2.47-5.86) for the total cholesterol to HDL-C (P<.001 for trend across all quintiles). The correlation coefficients between high-sensitivity CRP and the lipid parameters ranged from -0.33 to 0.15, and the clinical cut points for CRP of less than 1, 1 to 3, and higher than 3 mg/L provided prognostic information on risk across increasing levels of each lipid measure and lipid ratio.
CONCLUSIONS: Non-HDL-C and the ratio of total cholesterol to HDL-C were as good as or better than apolipoprotein fractions in the prediction of future cardiovascular events. After adjustment for age, blood pressure, smoking, diabetes, and obesity, high-sensitivity CRP added prognostic information beyond that conveyed by all lipid measures.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16030277     DOI: 10.1001/jama.294.3.326

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  207 in total

1.  Higher high-density lipoprotein cholesterol in African-American women with polycystic ovary syndrome compared with Caucasian counterparts.

Authors:  Kathryn W Koval; Tracy L Setji; Eric Reyes; Ann J Brown
Journal:  J Clin Endocrinol Metab       Date:  2010-06-09       Impact factor: 5.958

2.  The triglyceride:high-density lipoprotein-cholesterol ratio and steno-occlusive disease in the intracranial arteries.

Authors:  Kyusik Kang; Kwangsub Lee; Sung-Hoon Chung
Journal:  J Thromb Thrombolysis       Date:  2011-07       Impact factor: 2.300

3.  Association of apolipoprotein A1 and B with kidney function and chronic kidney disease in two multiethnic population samples.

Authors:  Oemer-Necmi Goek; Anna Köttgen; Ron C Hoogeveen; Christie M Ballantyne; Josef Coresh; Brad C Astor
Journal:  Nephrol Dial Transplant       Date:  2012-01-28       Impact factor: 5.992

4.  Stress and cardiovascular disease risk in female law enforcement officers.

Authors:  Hyelim Yoo; Warren D Franke
Journal:  Int Arch Occup Environ Health       Date:  2010-05-28       Impact factor: 3.015

5.  Effects of genetic variants on lipid parameters and dyslipidemia in a Chinese population.

Authors:  Yun Liu; Daizhan Zhou; Zhou Zhang; Yiqing Song; Di Zhang; Teng Zhao; Zhuo Chen; Yun Sun; Dabing Zhang; Yifeng Yang; Qinghe Xing; Xinzhi Zhao; He Xu; Lin He
Journal:  J Lipid Res       Date:  2010-12-12       Impact factor: 5.922

6.  Oral postmenopausal hormone therapy, C-reactive protein, and cardiovascular outcomes.

Authors:  Emily G Kurtz; Paul M Ridker; Lynda M Rose; Nancy R Cook; Brendan M Everett; Julie E Buring; Kathryn M Rexrode
Journal:  Menopause       Date:  2011-01       Impact factor: 2.953

Review 7.  Prevention of heart failure in the elderly: when, where and how to begin?

Authors:  Bodh I Jugdutt
Journal:  Heart Fail Rev       Date:  2012-09       Impact factor: 4.214

8.  Biomarkers and functional outcomes from ischaemic cerebral events in women: a prospective cohort study.

Authors:  P M Rist; J E Buring; C S Kase; P M Ridker; T Kurth
Journal:  Eur J Neurol       Date:  2012-10-03       Impact factor: 6.089

9.  VLDL best predicts aortic root atherosclerosis in LDL receptor deficient mice.

Authors:  Paul A VanderLaan; Catherine A Reardon; Ronald A Thisted; Godfrey S Getz
Journal:  J Lipid Res       Date:  2008-10-28       Impact factor: 5.922

10.  Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis.

Authors:  Calin Popa; Frank H J van den Hoogen; Timothy R D J Radstake; Mihai G Netea; Agnes E Eijsbouts; Martin den Heijer; Jos W M van der Meer; Piet L C M van Riel; Anton F H Stalenhoef; Pilar Barrera
Journal:  Ann Rheum Dis       Date:  2007-05-01       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.